CN107736959A - One kind, which can develop, carries medicine intravascular stent - Google Patents
One kind, which can develop, carries medicine intravascular stent Download PDFInfo
- Publication number
- CN107736959A CN107736959A CN201711222598.9A CN201711222598A CN107736959A CN 107736959 A CN107736959 A CN 107736959A CN 201711222598 A CN201711222598 A CN 201711222598A CN 107736959 A CN107736959 A CN 107736959A
- Authority
- CN
- China
- Prior art keywords
- intravascular stent
- drug
- rack body
- basalis
- develops
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/436—Inhibitors, antagonists of receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
It can develop the invention discloses one kind and carry medicine intravascular stent, be related to medical instruments field.The load medicine intravascular stent that develops of the present invention includes rack body, development structure and inner membrance；The rack body is in hollow tubular structure, and tube wall reticulates structure；It is described development structure setting in network structure hollow-out parts and be connected with rack body, it is described development body structure surface be fixed with developer；The rack body is set in outside the inner membrance, and the inner membrance includes basalis and drug-loaded layer；The basalis is respectively connecting to the rack body and the drug-loaded layer；The drug-loaded layer is fixed with treatment preparation.In the present invention on the one hand inner membrance prevents the formation of early stage thrombus by basalis, and the generation of ISR is on the other hand controlled by treating preparation, the patency of blood vessel after the intervention of common guarantee support.In addition, the intravascular stent is additionally provided with development structure, solves the not visible problem during intravascular stent implantation and Follow-up After, improve Clinical practicability.
Description
Technical field
It can develop the present invention relates to medical instruments field, especially one kind and carry medicine intravascular stent.
Background technology
Puncture shaping surgery, abbreviation PTA arts, it is under the guiding of medical imaging device, utilizes puncture needle, seal wire
The foley's tube for the support for being cased with tightening is injected human vas with guide sheath, and is transported at hemadostewnosis, with the expansion of sacculus
, support is also softened, and after sacculus contraction is withdrawn, the metallic support for producing plastic deformation then stays in original place, and embedded in blood vessel,
Play a part of expanding blood vessel.This method is widely used in treatment angiocarpy and periphery occlusive disease at present.According to statistics, at present
More than 80% angiocarpy and periphery occlusive disease is treated using this method.
Blood vessel after support intervention it is narrow be to limit the principal element further applied of this method.From current statistics
See, the incidence of ISR is 15%-30% after support intervention.Cardiovascular pharmacology research finds have multi-medicament can be in vitro
Obvious inhibitory action is produced to endangium and smooth muscle cell, but it is ineffective to carry out systemic administration, its reason may be with
Body-internal-circulation needs concentration too low relevant.
The content of the invention
The goal of the invention of the present invention is：For above-mentioned problem, there is provided one kind, which can develop, carries medicine intravascular stent, should
Intravascular stent has inner membrance, on the one hand prevents the formation of early stage thrombus, is on the other hand fixed with ISR after treatment support intervention
Healing potion, can effectively control the generation of postoperative restenosis, improve Clinical practicability.
The technical solution adopted by the present invention is as follows：
One kind, which can develop, carries medicine intravascular stent, and it includes rack body, development structure and inner membrance；The rack body is in hollow tube
Shape structure, tube wall reticulate structure；It is described development structure setting in network structure hollow-out parts and be connected with rack body, it is described
Development body structure surface is fixed with developer；The rack body is set in outside the inner membrance, and the inner membrance includes basalis and load
Medicine layer；The basalis is respectively connecting to the rack body and the drug-loaded layer；The drug-loaded layer is fixed with treatment preparation.
By adopting the above-described technical solution, on the one hand inner membrance prevents the formation of early stage thrombus, the opposing party by basalis
Face controls the generation of ISR by treating preparation, the patency of blood vessel after the intervention of common guarantee support.In addition, the intravascular stent
Development structure is additionally provided with, the not visible problem during intravascular stent implantation and Follow-up After is solved, improves clinical practice
Property.
It should be noted that the developer in the present invention is developer of the prior art, such as metallic gold (Au), metal platinum
(Pt), the larger metallics of the proportion such as tungsten (W).
The present invention one kind can develop carry medicine intravascular stent, the drug-loaded layer material be GMA-
Polylactic acid film；The drug-loaded layer thickness is 2-5 μm.
By adopting the above-described technical solution, the biocompatibility of drug-loaded layer is good, drugloading rate is big.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the basalis is material polysulfone resin film；The basalis
Thickness be 8-10 μm.
By adopting the above-described technical solution, polysulfone resin film is biomaterial commonly used in the prior art, its biofacies
Capacitive is high, and intensity is high, and stability is good.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the treatment preparation is angiotensin II receptor inhibitor.
By adopting the above-described technical solution, angiotensin II receptor inhibitor works from receptor blocking level, energy
Enough generations for slowing down or even eliminating reangiostenosis.Angiotensin II receptor inhibitor in the present invention is selected from Losartan, figured silk fabrics
One or more in Sha Tan, irbesartan, Candesartan, Irbesartan, Telmisartan.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the GMA-polylactic acid film leads to
Following method is crossed to be prepared：
According to mass ratio it is 2.3 by PLA and polyethylene glycol at 50 DEG C:0.7 be dissolved in dimethyl sulfoxide obtain PLA mixing
Liquid；It is 0.6 according to the mass ratio of GMA and PLA:1 adds methyl-prop into PLA mixed liquor
Olefin(e) acid ethylene oxidic ester, the azodiisobutyronitrile of addition catalytic amount after nitrogen 30min is passed through, is warming up to 60 DEG C under nitrogen protection
Carry out Raolical polymerizable 20h and obtain casting solution, reactor is poured into after casting solution deaeration filtering, with dry/wet induction inversion of phases
Method is spun into GMA-polylactic acid hollow fiber membrane；Hollow-fibre membrane is soaked with deionized water
24h, except residual solvent on striping, produce.
By adopting the above-described technical solution, GMA-the polylactic acid film is into hollow form, energy
The area of bigger fixation for treatment preparation is provided, and its cavity can also carry medicine by way of physics, further improve and carry
Dose.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the treatment preparation is fixed on the load medicine by the following method
Layer：
GMA-polylactic acid film is soaked in deionized water, according to tetramethylethylenediamine and methyl
The mass ratio of glycidyl acrylate-polylactic acid film is 0.1:3 add tetramethylethylenediamine, normal temperature into deionized water
Lower reaction 24h, GMA-polylactic acid film of diamines grafting is obtained, deionized water washes away unreacted
After tetramethyl diamines, it is soaked in fresh deionized water, according to treatment preparation and GMA-PLA
The mass ratio of film is 0.1:2 add treatment preparation into deionized water, and add the 1- ethyls of catalytic amount-（3- dimethyl
Aminopropyl）Carbodiimide hydrochloride, 16h is reacted under normal temperature, and deionized water washes away unreacted treatment preparation and produced.
By adopting the above-described technical solution, GMA-polylactic acid film is grafted by diamines, one
Increased activity after the grafting of aspect diamines, promote the chemical bond between treatment preparation；On the other hand, side chain lengthens, to treatment
The physical absorption enhancing of preparation, the two promotes the drugloading rate to treating preparation simultaneously.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the quantity of the development structure is at least four, and tube wall is by
Plane where the axis of hollow tube-like structure is divided into symmetrical upper tube wall and lower tube wall, and four development structures are located at upper tube respectively
The both ends of wall and lower tube wall.
By adopting the above-described technical solution, intravascular stent being capable of comprehensive, multi-angle development under medical imaging device.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the area of the development structure is place hollow out site area
40%-60%。
It should be noted that the development structure of the present invention can take different shapes.
By adopting the above-described technical solution, development structure possesses enough development effects；Can't be because of in support sheet
Over range arranges development structure and influences the mechanical property of rack body on body.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the drug-loaded layer is bonded in the substrate by high polymer binder
Layer.
One kind of the present invention, which can develop, carries medicine intravascular stent, and the high polymer binder is selected from PLLA, gathers outer disappear
Revolve the one or more in lactic acid, PCL, PTMC.
By adopting the above-described technical solution, the bonding between rack body, basalis and drug-loaded layer three is realized,
And avoid the destruction to rack body.
In summary, by adopting the above-described technical solution, the beneficial effects of the invention are as follows：
1. the intravascular stent has inner membrance, the treatment preparation that medicine inner membrance is fixed with ISR after treatment support intervention is carried, can be effective
The generation of postoperative restenosis is controlled, improves Clinical practicability.
2. drug-loaded layer is in hollow structure, medicine is carried by physics and chemical two ways, drugloading rate is big.
3. the intravascular stent is additionally provided with development structure, solve during intravascular stent implantation and Follow-up After can not
Depending on problem, Clinical practicability is improved.
Brief description of the drawings
Examples of the present invention will be described by way of reference to the accompanying drawings, wherein：
Fig. 1 developments provided by the invention carry the structural representation of medicine intravascular stent.
In figure, 1 is rack body, and 12 be upper tube wall, and 13 be lower tube wall, and 3 be development structure.
Embodiment
All features disclosed in this specification, or disclosed all methods or during the step of, except mutually exclusive
Feature and/or step beyond, can combine in any way.
This specification（Including any accessory claim, summary）Disclosed in any feature, unless specifically stated otherwise,
Replaced by other equivalent or with similar purpose alternative features.I.e., unless specifically stated otherwise, each feature is a series of
An example in equivalent or similar characteristics.
Embodiment 1
The present embodiment, which provides one kind, can develop intravascular stent, and it includes rack body 1, development structure 3 and inner membrance, rack body 1
It is set in inner membrance.Development structure 3 is arranged at rack body 1.
Rack body 1 is in hollow tubular structure, and tube wall is into hollow mesh structure.Rack body 1 is by hollow tubular structure
Plane where axis is divided into symmetrical upper tube wall 12 and lower tube wall 13.Rack body 1 in the present embodiment can use existing
Being arbitrarily made for implantable material in technology, such as medical stainless steel or medical macromolecular materials.The diameter of rack body 1
It is gradually reduced from centre to both ends, the 75%-80% of a diameter of middle part diameter in both ends.Anti-skidding blood vessel branch provided by the invention
Frame, the length of rack body 1 is 0.5-20cm, a diameter of 1.0-8.0cm of rack body 1.
Inner membrance includes basalis and drug-loaded layer（It is not shown）, substrate is laminated to be connected to rack body 1, and another side is connected to
Drug-loaded layer.Basalis material is polysulfone resin film of the prior art, and the thickness of basalis is 8-10 μm.Drug-loaded layer material is first
Base glycidyl acrylate-polylactic acid film, drug-loaded layer thickness are 2-5 μm.
In the present embodiment, basalis is bonded in rack body 1 by high polymer binder, and drug-loaded layer is glued by high polymer binder
Tie in the basalis.High polymer binder is selected from PLLA, poly- racemic lactic acid, PCL, polytrimethylene
One or more in carbonic ester.
Development structure 3 is arranged at the netted hollow-out parts of rack body 1, and is connected with rack body 1.Structure 3 of developing
The 40%-60% of area area at hollow out position where it.Preferably, the quantity for structure 3 of developing is at least four.When with four
During individual development structure 3, four development structures 3 are respectively positioned at the both ends of upper tube wall 12 and lower tube wall 13.When development structure 3 is more than four
When individual, it is uniformly distributed in tube wall.Development structure 3 surface is fixed with developer, and developer is developer of the prior art, such as
The larger metallicses of proportion such as metallic gold (Au), metal platinum (Pt), tungsten (W).
Embodiment 2
The present embodiment provides a kind of GMA-polylactic acid film, and the film is in hollow form, can in its cavity
Accommodate guest molecule, increase and the contact area of guest molecule.GMA-the polylactic acid film passes through such as
Lower section method is prepared：
It is 2.3 according to mass ratio:0.7 weighs PLA and polyethylene glycol respectively, is scattered in dimethyl sulfoxide, is heated to 50
DEG C obtain PLA mixed liquor；It is 0.6 according to the mass ratio of GMA and PLA:1 weighs methyl-prop
Olefin(e) acid ethylene oxidic ester, and add into PLA mixed liquor, nitrogen 30min is passed through after stirring, forms nitrogen protection, so
The azodiisobutyronitrile of catalytic amount is added afterwards, is warming up to 60 DEG C and is maintained to carry out Raolical polymerizable 20h under nitrogen protection
Casting solution is obtained, reactor is poured into after casting solution deaeration filtering, Glycidyl methacrylate is spun into dry/wet induction phase inversion
Glyceride-polylactic acid hollow fiber membrane；By hollow-fibre membrane with soaking 24h in deionized water, except remaining dimethyl sulfoxide on striping,
Produce.
Embodiment 3
The present embodiment provides a kind of hollow GMA-polylactic acid film diamines grafting by embodiment 2
Mixed afterwards with Losartan to Losartan while carry out the method that physics and chemistry carry medicine, this method comprises the following steps：
GMA-polylactic acid film is soaked in deionized water, according to tetramethylethylenediamine and methyl
The mass ratio of glycidyl acrylate-polylactic acid film is 0.1:3 add tetramethylethylenediamine, normal temperature into deionized water
Lower reaction 24h, GMA-polylactic acid film of diamines grafting is obtained, deionized water washes away unreacted
After tetramethyl diamines, it is soaked in fresh deionized water, according to treatment preparation and GMA-PLA
The mass ratio of film is 0.1:2 add treatment preparation into deionized water, and add the 1- ethyls of catalytic amount-（3- dimethyl
Aminopropyl）Carbodiimide hydrochloride, 16h is reacted under normal temperature, and deionized water washes away unreacted treatment preparation and produced.
The invention is not limited in foregoing embodiment.The present invention, which expands to, any in this manual to be disclosed
New feature or any new combination, and disclose any new method or process the step of or any new combination.
Claims (10)
1. one kind, which can develop, carries medicine intravascular stent, it is characterised in that it includes rack body, development structure and inner membrance；The branch
Frame body is in hollow tubular structure, and tube wall reticulates structure；It is described development structure setting in network structure hollow-out parts and with branch
Frame body is connected, and the development body structure surface is fixed with developer；The rack body is set in outside the inner membrance, the inner membrance
Including basalis and drug-loaded layer；The basalis is respectively connecting to the rack body and the drug-loaded layer；The drug-loaded layer is consolidated
Surely there is treatment preparation.
2. the load medicine intravascular stent according to claim 1 that develops, it is characterised in that the drug-loaded layer material is methyl-prop
Olefin(e) acid ethylene oxidic ester-polylactic acid film；The drug-loaded layer thickness is 2-5 μm.
3. the load medicine intravascular stent according to claim 2 that develops, it is characterised in that the basalis is material polysulfones tree
Adipose membrane；The thickness of the basalis is 8-10 μm.
4. the load medicine intravascular stent according to claim 3 that develops, it is characterised in that the treatment preparation is vasotonia
Plain II acceptor inhibitor.
5. the load medicine intravascular stent according to claim 4 that develops, it is characterised in that the methyl propenoic acid glycidyl
Ester-polylactic acid film is prepared via a method which to form：
According to mass ratio it is 2.3 by PLA and polyethylene glycol at 50 DEG C:0.7 be dissolved in dimethyl sulfoxide obtain PLA mixing
Liquid；It is 0.6 according to the mass ratio of GMA and PLA:1 adds methyl-prop into PLA mixed liquor
Olefin(e) acid ethylene oxidic ester, the azodiisobutyronitrile of addition catalytic amount after nitrogen 30min is passed through, is warming up to 60 DEG C under nitrogen protection
Carry out Raolical polymerizable 20h and obtain casting solution, reactor is poured into after casting solution deaeration filtering, with dry/wet induction inversion of phases
Method is spun into GMA-polylactic acid hollow fiber membrane；Hollow-fibre membrane is soaked with deionized water
24h, except residual solvent on striping, produce.
6. the load medicine intravascular stent according to claim 5 that develops, it is characterised in that the treatment preparation passes through such as lower section
Method is fixed on the drug-loaded layer：
GMA-polylactic acid film is soaked in deionized water, according to tetramethylethylenediamine and methyl
The mass ratio of glycidyl acrylate-polylactic acid film is 0.1:3 add tetramethylethylenediamine, normal temperature into deionized water
Lower reaction 24h, GMA-polylactic acid film of diamines grafting is obtained, deionized water washes away unreacted
After tetramethyl diamines, it is soaked in fresh deionized water, according to treatment preparation and GMA-PLA
The mass ratio of film is 0.1:2 add treatment preparation into deionized water, and add the 1- ethyls of catalytic amount-（3- dimethyl
Aminopropyl）Carbodiimide hydrochloride, 16h is reacted under normal temperature, and deionized water washes away unreacted treatment preparation and produced.
7. the load medicine intravascular stent according to claim 1 that develops, it is characterised in that the quantity of the development structure is at least
For four, tube wall is divided into symmetrical upper tube wall and lower tube wall, four developments by the plane where the axis of hollow tubular structure
Structure is respectively positioned at the both ends of upper tube wall and lower tube wall.
8. the load medicine intravascular stent according to claim 7 that develops, it is characterised in that the area of the development structure is institute
In the 40%-60% of hollow out site area.
9. the intravascular stent that develops according to any one of claim 1-8, it is characterised in that the basalis is by height
Molecular binder is bonded in rack body；The drug-loaded layer is bonded in the basalis by high polymer binder.
10. the load medicine intravascular stent according to claim 9 that develops, it is characterised in that the high polymer binder is selected from poly-
One or more in D-lactic acid, poly- racemic lactic acid, PCL, PTMC.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711222598.9A CN107736959A (en) | 2017-11-29 | 2017-11-29 | One kind, which can develop, carries medicine intravascular stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711222598.9A CN107736959A (en) | 2017-11-29 | 2017-11-29 | One kind, which can develop, carries medicine intravascular stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107736959A true CN107736959A (en) | 2018-02-27 |
Family
ID=61239637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711222598.9A Withdrawn CN107736959A (en) | 2017-11-29 | 2017-11-29 | One kind, which can develop, carries medicine intravascular stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107736959A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11506620B1 (en) | 2018-07-20 | 2022-11-22 | United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Control of oxygen fugacity in a high pressure solid media assembly using a double capsule |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101094698A (en) * | 2003-09-29 | 2007-12-26 | 汉莫堤克科技公司 | Biocompatible, biostable coating of medical surfaces |
| US20100004735A1 (en) * | 2008-05-02 | 2010-01-07 | Arlene Sucy Yang | Polymeric Stent |
| CN102430157A (en) * | 2011-11-29 | 2012-05-02 | 武汉纺织大学 | Medical scaffold with inner coating film, and preparation method for medical scaffold |
| CN103316596A (en) * | 2013-05-14 | 2013-09-25 | 中国科学院宁波材料技术与工程研究所 | Preparation method of anticoagulation polylactic acid hemodialysis membrane |
| CN103930074A (en) * | 2011-05-22 | 2014-07-16 | 东莞天天向上医疗科技有限公司 | Biodegradable drug-eluitng stent patten |
| CN105193532A (en) * | 2015-10-30 | 2015-12-30 | 加奇生物科技（上海）有限公司苏州分公司 | Carotid artery stent system |
| CN105457105A (en) * | 2015-07-24 | 2016-04-06 | 中国科学院金属研究所 | Novel developable magnesium alloy intravascular stent |
| CN106333773A (en) * | 2015-07-07 | 2017-01-18 | 先健科技(深圳)有限公司 | Blood vessel stent |
-
2017
- 2017-11-29 CN CN201711222598.9A patent/CN107736959A/en not_active Withdrawn
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101094698A (en) * | 2003-09-29 | 2007-12-26 | 汉莫堤克科技公司 | Biocompatible, biostable coating of medical surfaces |
| US20100004735A1 (en) * | 2008-05-02 | 2010-01-07 | Arlene Sucy Yang | Polymeric Stent |
| CN103930074A (en) * | 2011-05-22 | 2014-07-16 | 东莞天天向上医疗科技有限公司 | Biodegradable drug-eluitng stent patten |
| CN102430157A (en) * | 2011-11-29 | 2012-05-02 | 武汉纺织大学 | Medical scaffold with inner coating film, and preparation method for medical scaffold |
| CN103316596A (en) * | 2013-05-14 | 2013-09-25 | 中国科学院宁波材料技术与工程研究所 | Preparation method of anticoagulation polylactic acid hemodialysis membrane |
| CN106333773A (en) * | 2015-07-07 | 2017-01-18 | 先健科技(深圳)有限公司 | Blood vessel stent |
| CN105457105A (en) * | 2015-07-24 | 2016-04-06 | 中国科学院金属研究所 | Novel developable magnesium alloy intravascular stent |
| CN105193532A (en) * | 2015-10-30 | 2015-12-30 | 加奇生物科技（上海）有限公司苏州分公司 | Carotid artery stent system |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11506620B1 (en) | 2018-07-20 | 2022-11-22 | United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Control of oxygen fugacity in a high pressure solid media assembly using a double capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | Mussel-inspired conductive nanofibrous membranes repair myocardial infarction by enhancing cardiac function and revascularization | |
| CN102791183B (en) | Embolization device constructed from expansile polymer | |
| ES2408014T3 (en) | Hydrogels that undergo volumetric expansion in response to changes in their environment and methods for their manufacture and use | |
| EP4169960A1 (en) | Temperature-dependent shape memory polymer | |
| JPH07500037A (en) | Collagen composition | |
| JPWO2008016163A1 (en) | Cross-linked gelatin gel multilayer structure, bioactive factor carrier, bioactive factor releasing preparation, and method for producing them | |
| EP2921148A1 (en) | Dressing for compromised wound healing | |
| Cutiongco et al. | Composite scaffold of poly (vinyl alcohol) and interfacial polyelectrolyte complexation fibers for controlled biomolecule delivery | |
| Yuan et al. | One-pot preparation of polymer microspheres with different porous structures to sequentially release bio-molecules for cutaneous regeneration | |
| KR20200115342A (en) | Hydrogel structure with microchannel network | |
| CN107736959A (en) | One kind, which can develop, carries medicine intravascular stent | |
| CN110872364A (en) | Gel with shape memory function, preparation method and anticoagulation blood vessel stent | |
| CN112043878B (en) | A kind of anticoagulant tube stent coating and preparation method thereof | |
| Shi et al. | Dissolvable hybrid microneedle patch for efficient delivery of curcumin to reduce intraocular inflammation | |
| Zhao et al. | Boost tendon/ligament repair with biomimetic and smart cellular constructs | |
| CN107669380A (en) | A kind of drug eluting vascular support | |
| CN107669381A (en) | A kind of medicament-release blood vessel stent | |
| Liu et al. | Controlling the biointerface of electrospun mats for clot lysis: an engineered tissue plasminogen activator link to a lysine-functionalized surface | |
| CN107736960A (en) | One kind, which can develop, carries medicine titanium alloy support | |
| CN104927003B (en) | A kind of preparation and application of the soybean protein based high molecular gel with good biocompatibility and swelling behavior | |
| CN110669184A (en) | A kind of preparation method of shape memory polymer material with drug release function, obtained product and application | |
| JP3599749B2 (en) | Biodegradable polymer networks for use in orthopedic and dental applications | |
| JP2004344627A (en) | Balloon catheter for medical treatment | |
| JPWO2020071429A1 (en) | Angiogenesis promoter and treatment method | |
| CN107736958A (en) | A kind of titanium alloy medicament-release blood vessel stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180227 |
|
| WW01 | Invention patent application withdrawn after publication |